CSL Ltd. — Capital/Financing Update 2020

Nov 15, 2020

For immediate release

16 November 2020

==> picture [205 x 32] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Next-generation influenza vaccine manufacturing facility to be built in Australia

AUD$800m investment optimises cell-based technology

Global biotechnology leader CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that Seqirus, a wholly owned subsidiary of CSL, plans to invest more than AUD$800 million in the construction of a new biotech manufacturing facility in Melbourne to supply influenza vaccines to Australia and the rest of the world.

This investment decision follows the agreement with the Australian Government for the supply over 10 years of influenza pandemic protection for the Australian population, antivenoms for Australian snakes, spiders and marine creatures and Q-Fever vaccine.

The new facility, to be built at a site in the Melbourne Airport Business Park, will use innovative cell-based technology to produce influenza vaccine for both seasonal and pandemic purposes. These products will serve the needs of the Australian population and have capacity to support global markets. Construction of the state-of-the-art plant is expected to commence in 2021 with the facility projected to be operational by mid-2026.

The facility will also manufacture Seqirus’ proprietary adjuvant MF59® - a substance added to some vaccines to improve immune response and to reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly.

CSL’s Chief Executive Officer and Managing Director Paul Perreault said, “Providing safe and effective influenza vaccines is essential in securing our defences against serious public health threats.”

“The facility will be an important addition to our global influenza manufacturing supply chain, incorporating the technology platform used in our Holly Springs, North Carolina facility. Cell-influenza vaccine technology offers many advantages over the existing process including being more scalable and offering faster production – particularly important in the case of influenza pandemics.

“As a proudly Australian company, we are pleased to make this investment in worldclass advanced manufacturing. This decision will ensure the future of 1,000+ Science Technology Engineering & Manufacturing jobs in Victoria and a supply chain of more than $300 million annually,” he said.

==> picture [99 x 7] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Page 2

The Victorian Government will also contribute to the project to reinforce Victoria’s already globally significant medical research and biotechnology community.

Authorised by Fiona Mead Company Secretary

FURTHER INFORMATION

For further information, please contact:

Investors: Mark Dehring Head of Investor Relations CSL Limited Telephone: +613 9389 3407 Email: mark.dehring@csl.com.au

Media: Christina Hickie Senior Manager, Communications CSL Limited +61 429 609 762 Email: christina.hickie@csl.com.au

® Trademarks of CSL Limited or its affiliates.

==> picture [99 x 7] intentionally omitted <==